J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The discovery may explain why cutting edge CAR T-cell therapy has managed to revolutionized treatment for blood cancer but ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

The global Liquid Biopsy Market is valued at USD 11.41 Billion in 2024 and is projected to reach a value of USD 30.65 Billion ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Molecular profiling could reduce both overtreatment and undertreatment of patients with high-intermediate risk endometrial ...

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, today announced the signing of a Memorandum of Understanding (MOU) with ChiMei Medical Center (CMMC), a premier ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

As per the recent health updates, Shoaib shared that though Dipika has undergone a surgery, there is a high risk of cancer ...